Article

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell cultures

2019-10-10

Abstract excerpt

Respiratory syncytial virus (RSV) causes severe lower respiratory tract infections in young infants. There are no RSV-specific treatments available. Ablynx has been developing an anti-RSV F-specific Nanobody®, ALX-0171. To characterise the therapeutic potential of ALX-0171 we exploited our well-differentiated primary pediatric bronchial epithelial cell (WD-PBEC)/RSV infection model, which replicates several hallma...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 85b843f2-2d21-5d44-baed-27de8124d080
DOI: 10.1101/800326

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparative therapeutic potential of ALX-0171 and palivizumab against RSV clinical isolate infection of well-differentiated primary pediatric bronchial epithelial cell culturesDOI 10.1101/800326Read

Multiple RSV strains infecting HEp-2 and A549 cells reveal cell line-dependent differences in resistance to RSV infectionSemantic proximity Read

Reverse genetics systems for contemporary isolates of respiratory syncytial virus enable rapid evaluation of antibody escape mutants.Semantic proximity Read

Respiratory syncytial virus nonstructural protein 1 inhibits production of cytokines and chemokines by differentiated primary nasal epithelial cells cultured at air-liquid interfaceSemantic proximity Read

The human nose organoid respiratory virus model: an ex-vivo human challenge model to study RSV and SARS-CoV-2 pathogenesis and evaluate therapeuticsSemantic proximity Read

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate modelSemantic proximity Read

Respiratory Syncytial Virus Nonstructural Protein 1 Inhibits Production of Cytokines and Chemokines by Differentiated Primary Nasal Epithelial Cells Cultured at Air-Liquid Interface.Semantic proximity Read

Drug candidates and model systems in respiratory syncytial virus antiviral drug discovery.Semantic proximity Read

Antiviral drug synergy and mutational signatures in different epithelial cell models of RSV and hPIV infectionSemantic proximity Read

Multiple Respiratory Syncytial Virus (RSV) Strains Infecting HEp-2 and A549 Cells Reveal Cell Line-Dependent Differences in Resistance to RSV InfectionSemantic proximity Read

RSV--a substantial slice of the airway disease burden and the way to a vaccine.Semantic proximity Read

Mechanism of Action for Respiratory Syncytial Virus Inhibitor RSV604Semantic proximity Read

Discovery of a Novel Respiratory Syncytial Virus Replication InhibitorSemantic proximity Read